Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170621 | 1.00 | CRBN (0.35) | CRBNTAS2R38 | |
| SCHEMBL6560044 | 1.00 | CRBN (0.35) | CRBNTAS2R38 | |
| SCHEMBL11698336 | 0.84 | CRBN (0.33) | CRBNTAS2R38 | |
| SCHEMBL25480034 | 0.80 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL3753647 | 0.78 | — | — | |
| SCHEMBL13219908 | 0.78 | — | — | |
| SCHEMBL3753641 | 0.78 | — | — | |
| SCHEMBL15084705 | 0.77 | — | — | |
| SCHEMBL10329427 | 0.76 | ALDH1A1 (0.31) | — | |
| SCHEMBL21359614 | 0.74 | DGAT1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239007-A1 | BENZIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR INFECTIOUS DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239007-A1 | BENZIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR INFECTIOUS DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| US-11708352-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-25 | — | — | US | disclosed |
| US-10562886-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180354932-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-12-13 | — | — | US | disclosed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20160289175-A1 | CREATINE ANALOGS AND THE USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2016-10-06 | — | — | US | disclosed |
| EP-1391454-B1 | Substituted benzamide compounds with antihypertensive activity | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1391454-A1 | Substituted benzamide compounds with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-6156766-A | Benzamide compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| EP-0641781-B1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5958944-A | TREATMENT OF CIRCULATORY DISEASES IN CORONARY, CEREBRAL, RENAL AND PERIPHERAL ARTERIES, AS A THERAPEUTIC AGENT FOR HYPERTENSION, ANGINA PECTORIS, AND RENAL AND PERIPHERAL CIRCULATION DISORDER, ANTIASTHMATIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
| US-5478838-A | Treating hypertension, angina pectoris, asthma, improving peripheral circulation | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0641781-A1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562886-B2 | Anti-cancer compounds | TP53, VHL, BAD | CRBN 1412/4885TAS2R38 4715/4885 |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | TIE1, KDR, FLT4 | CRBN 408/4885TAS2R38 2546/4885 |
| US-20180354932-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | CRBN 1412/4885TAS2R38 4715/4885 |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | CRBN 4816/4885TAS2R38 4689/4885 |
| US-11708352-B2 | Anti-cancer compounds | TP53, VHL, BAD | CRBN 1412/4885TAS2R38 4715/4885 |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | CRBN 1412/4885TAS2R38 4715/4885 |
| US-20160289175-A1 | CREATINE ANALOGS AND THE USE THEREOF | CKMT1A; CKMT1B, CPT1B, GLS | CRBN 1682/4885TAS2R38 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.